BMP15 mutations associated with primary ovarian insufficiency reduce expression, activity, or synergy with gdf9

Liliana C. Patino, Kelly L. Walton, Thomas D. Mueller, Katharine E. Johnson, William Stocker, Dulama Richani, David Agapiou, Robert B. Gilchrist, Paul Laissue, Craig A. Harrison

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Context: Bone morphogenetic protein (BMP)15 is an oocyte-specific growth factor, which, together with growth differentiation factor (GDF) 9, regulates folliculogenesis and ovulation rate. Multiple mutations in BMP15 have been identified in women with primary ovarian insufficiency (POI), supporting a pathogenic role; however, the underlying biological mechanism of many of these mutants remains unresolved. Objectives: To determine how mutations associated with ovarian dysfunction alter the biological activity of human BMP15. Design: The effects of 10 mutations in BMP15 on protein production, activation of granulosa cells, and synergy with GDF9 were assessed. Results: Sequencing of 35 patients with POI identified both an unrecognized BMP15 variant (c.986G.A, R329H) and a variant (c.581T.C, F194S) previously associated with the condition. Assessing expression and activity of these and 8 other BMP15 mutants identified: (1) multiple variants, including L148P, F194S, and Y235C, with reduced mature protein production; (2) three variants (R138H, A180T, and R329H) with ;fourfold lower activity than wild-type BMP15; and (3) 3 variants (R68W, F194S, and N196K) with a significantly reduced ability to synergize with GDF9. Conclusions: Mutations in BMP15 associated with POI reduce mature protein production, activity, or synergy with GDF9. The latter effect is perhaps most interesting given that interactions with GDF9 most likely underlie the physiology of BMP15 in the human ovary.

Original languageEnglish
Pages (from-to)1009-1019
Number of pages11
JournalJournal of Clinical Endocrinology and Metabolism
Volume102
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • turner's syndrome
  • mutation
  • ovary
  • physiology

Cite this

Patino, Liliana C. ; Walton, Kelly L. ; Mueller, Thomas D. ; Johnson, Katharine E. ; Stocker, William ; Richani, Dulama ; Agapiou, David ; Gilchrist, Robert B. ; Laissue, Paul ; Harrison, Craig A. / BMP15 mutations associated with primary ovarian insufficiency reduce expression, activity, or synergy with gdf9. In: Journal of Clinical Endocrinology and Metabolism. 2017 ; Vol. 102, No. 3. pp. 1009-1019.
@article{a0aacd7cf1a04d34b6463d53f7a4f9a8,
title = "BMP15 mutations associated with primary ovarian insufficiency reduce expression, activity, or synergy with gdf9",
abstract = "Context: Bone morphogenetic protein (BMP)15 is an oocyte-specific growth factor, which, together with growth differentiation factor (GDF) 9, regulates folliculogenesis and ovulation rate. Multiple mutations in BMP15 have been identified in women with primary ovarian insufficiency (POI), supporting a pathogenic role; however, the underlying biological mechanism of many of these mutants remains unresolved. Objectives: To determine how mutations associated with ovarian dysfunction alter the biological activity of human BMP15. Design: The effects of 10 mutations in BMP15 on protein production, activation of granulosa cells, and synergy with GDF9 were assessed. Results: Sequencing of 35 patients with POI identified both an unrecognized BMP15 variant (c.986G.A, R329H) and a variant (c.581T.C, F194S) previously associated with the condition. Assessing expression and activity of these and 8 other BMP15 mutants identified: (1) multiple variants, including L148P, F194S, and Y235C, with reduced mature protein production; (2) three variants (R138H, A180T, and R329H) with ;fourfold lower activity than wild-type BMP15; and (3) 3 variants (R68W, F194S, and N196K) with a significantly reduced ability to synergize with GDF9. Conclusions: Mutations in BMP15 associated with POI reduce mature protein production, activity, or synergy with GDF9. The latter effect is perhaps most interesting given that interactions with GDF9 most likely underlie the physiology of BMP15 in the human ovary.",
keywords = "turner's syndrome, mutation, ovary, physiology",
author = "Patino, {Liliana C.} and Walton, {Kelly L.} and Mueller, {Thomas D.} and Johnson, {Katharine E.} and William Stocker and Dulama Richani and David Agapiou and Gilchrist, {Robert B.} and Paul Laissue and Harrison, {Craig A.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1210/jc.2016-3503",
language = "English",
volume = "102",
pages = "1009--1019",
journal = "Journal of Clinical Endocrinology and Metablism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

BMP15 mutations associated with primary ovarian insufficiency reduce expression, activity, or synergy with gdf9. / Patino, Liliana C.; Walton, Kelly L.; Mueller, Thomas D.; Johnson, Katharine E.; Stocker, William; Richani, Dulama; Agapiou, David; Gilchrist, Robert B.; Laissue, Paul; Harrison, Craig A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 102, No. 3, 01.03.2017, p. 1009-1019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - BMP15 mutations associated with primary ovarian insufficiency reduce expression, activity, or synergy with gdf9

AU - Patino, Liliana C.

AU - Walton, Kelly L.

AU - Mueller, Thomas D.

AU - Johnson, Katharine E.

AU - Stocker, William

AU - Richani, Dulama

AU - Agapiou, David

AU - Gilchrist, Robert B.

AU - Laissue, Paul

AU - Harrison, Craig A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Context: Bone morphogenetic protein (BMP)15 is an oocyte-specific growth factor, which, together with growth differentiation factor (GDF) 9, regulates folliculogenesis and ovulation rate. Multiple mutations in BMP15 have been identified in women with primary ovarian insufficiency (POI), supporting a pathogenic role; however, the underlying biological mechanism of many of these mutants remains unresolved. Objectives: To determine how mutations associated with ovarian dysfunction alter the biological activity of human BMP15. Design: The effects of 10 mutations in BMP15 on protein production, activation of granulosa cells, and synergy with GDF9 were assessed. Results: Sequencing of 35 patients with POI identified both an unrecognized BMP15 variant (c.986G.A, R329H) and a variant (c.581T.C, F194S) previously associated with the condition. Assessing expression and activity of these and 8 other BMP15 mutants identified: (1) multiple variants, including L148P, F194S, and Y235C, with reduced mature protein production; (2) three variants (R138H, A180T, and R329H) with ;fourfold lower activity than wild-type BMP15; and (3) 3 variants (R68W, F194S, and N196K) with a significantly reduced ability to synergize with GDF9. Conclusions: Mutations in BMP15 associated with POI reduce mature protein production, activity, or synergy with GDF9. The latter effect is perhaps most interesting given that interactions with GDF9 most likely underlie the physiology of BMP15 in the human ovary.

AB - Context: Bone morphogenetic protein (BMP)15 is an oocyte-specific growth factor, which, together with growth differentiation factor (GDF) 9, regulates folliculogenesis and ovulation rate. Multiple mutations in BMP15 have been identified in women with primary ovarian insufficiency (POI), supporting a pathogenic role; however, the underlying biological mechanism of many of these mutants remains unresolved. Objectives: To determine how mutations associated with ovarian dysfunction alter the biological activity of human BMP15. Design: The effects of 10 mutations in BMP15 on protein production, activation of granulosa cells, and synergy with GDF9 were assessed. Results: Sequencing of 35 patients with POI identified both an unrecognized BMP15 variant (c.986G.A, R329H) and a variant (c.581T.C, F194S) previously associated with the condition. Assessing expression and activity of these and 8 other BMP15 mutants identified: (1) multiple variants, including L148P, F194S, and Y235C, with reduced mature protein production; (2) three variants (R138H, A180T, and R329H) with ;fourfold lower activity than wild-type BMP15; and (3) 3 variants (R68W, F194S, and N196K) with a significantly reduced ability to synergize with GDF9. Conclusions: Mutations in BMP15 associated with POI reduce mature protein production, activity, or synergy with GDF9. The latter effect is perhaps most interesting given that interactions with GDF9 most likely underlie the physiology of BMP15 in the human ovary.

KW - turner's syndrome

KW - mutation

KW - ovary

KW - physiology

UR - http://www.scopus.com/inward/record.url?scp=85015234095&partnerID=8YFLogxK

U2 - 10.1210/jc.2016-3503

DO - 10.1210/jc.2016-3503

M3 - Article

VL - 102

SP - 1009

EP - 1019

JO - Journal of Clinical Endocrinology and Metablism

JF - Journal of Clinical Endocrinology and Metablism

SN - 0021-972X

IS - 3

ER -